A pharmacy led program to review anti-psychotic prescribing for people with dementia

BMC Psychiatry

Ian Maidment⁴  Chris Fox³  Amy Clarke¹  Anne Child² 

[1] NHS Medway, 50 Pembroke Court, Chatham Maritime, Chatham, Kent, ME4 4EL, UK;Avante Care and Support, De Gelsey House, 1 Jubilee Way, Faversham, Kent, ME13 8GD, UK;Faculty of Medicine and Health Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK;Pharmacy, School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, B4 7ET, UK

关键词: Dementia Registers;    Medication Review;    National Dementia Strategy;    Anti-psychotics;   

Others  :  1124276
DOI  :  10.1186/1471-244X-12-155

 received in 2012-05-01, accepted in 2012-09-20,  发布年份 2012

【 摘 要 】

Background

Anti-psychotics, prescribed to people with dementia, are associated with approximately 1,800 excess annual deaths in the UK. A key public health objective is to limit such prescribing of anti-psychotics.

Methods

This project was conducted within primary care in Medway Primary Care Trust (PCT) in the UK. There were 2 stages for the intervention. First, primary care information systems including the dementia register were searched by a pharmacy technician to identify people with dementia prescribed anti-psychotics. Second, a trained specialist pharmacist conducted targeted clinical medication reviews in people with dementia initiated on anti-psychotics by primary care, identified by the data search.

Results

Data were collected from 59 practices. One hundred and sixty-one (15.3%) of 1051 people on the dementia register were receiving low-dose anti-psychotics. People with dementia living in residential homes were nearly 3.5 times more likely to receive an anti-psychotic [25.5% of care home residents (118/462) vs. 7.3% of people living at home (43/589)] than people living in their own homes (p < 0.0001; Fisher’s exact test). In 26 practices there was no-one on the dementia register receiving low-dose anti-psychotics.

Of the 161 people with dementia prescribed low-dose anti-psychotics, 91 were receiving on-going treatment from local secondary care mental health services or Learning Disability Teams. Of the remaining 70 patients the anti-psychotic was either withdrawn, or the dosage was reduced, in 43 instances (61.4%) following the pharmacy-led medication review.

Conclusions

In total 15.3% of people on the dementia register were receiving a low-dose anti-psychotic. However, such data, including the recent national audit may under-estimate the usage of anti-psychotics in people with dementia. Anti-psychotics were used more commonly within care home settings. The pharmacist-led medication review successfully limited the prescribing of anti-psychotics to people with dementia.

【 授权许可】

   
2012 Child et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Alzheimer’s Disease International: World Alzheimer Report. 2009. Available on www.alz.co.uk/research/files/WorldAlzheimerReport.pdf webcite (accessed 21st January 2012)
• [2]Department of Health: Living well with dementia: a national dementia strategy. London, Stationary Office. 2009. Available on http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_094051.pdf webcite (accessed 31st January 2012)
• [3]Health and Social Care Information Centre (HSCIC): National Dementia and Anti-psychotic Prescribing Audit. 2012. Available on www.ic.nhs.uk/dementiaaudit webcite (accessed 31st July 2012)
• [4]Savva GM, Zaccai J, Matthews FE, Davidson JE, McKeith I, Brayne C: Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Br J Psychiatry 2009, 2009:212-219.
• [5]Ballard C, Waite J: Atypical anti-psychotics for aggression and psychosis in Alzheimer’s disease. Cochrane Database of Systematic Reviews 2006, Issue 1. Cochrane Collaboration. John Wiley & Sons, Ltd;
• [6]Parnetti L, Amici S, Lanari A, Gallai V: Pharmacological treatment of non-cognitive disturbances in dementia disorders. Mech Ageing Dev 2001, 122:2063-2069.
• [7]Torti FM, Gwyther LP, Reed SD, Friedman JY, Schulman KA: A multinational review of recent trends and reports in dementia caregiver burden. Alzh Dis Ass Disord 2004, 18:99-109.
• [8]Gallicchio L, Siddiqi N, Langenberg P, Baumgarten M: Gender differences in burden and depression among informal caregivers of demented elders in the community. Int J Geriatr Psychiatry 2002, 17:154-163.
• [9]Gaugler JE, Kane RL, Kane RA, Newcomer R: Unmet care needs and key outcomes in dementia. JAGS 2005, 53:2098-2105.
• [10]Etters L, Goodall D, Harrison BE: Caregiver burden among dementia patient caregivers: A review of the literature. J Am Acad Nurse Pract 2008, 20:423-428.
• [11]Souetre E, Thwaites RMA, Yeardley HL: Economic impact of Alzheimer’s disease in the United Kingdom: Cost of care and disease severity for non-institutionalized patients with Alzheimer’s disease. Br J Psychiatry 1999, 174:51-55.
• [12]Gaugler JE, Yu F, Krichbaum K, Wyman JF: Predictors of nursing home admission for person with dementia. Med Care 2009, 47:191-198.
• [13]Department of Health: National Service Framework for Older People. London, Stationary Office. 2001. Available on http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4071283.pdf webcite (accessed 14th April)
• [14]Department of Health: The use of anti-psychotic medication for people with dementia: Time for action Living well with dementia: A National Dementia Strategy. London: Stationary Office; 2009. Available on www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_108303 webcite(accessed 14th April)
• [15]Department of Health: Quality outcomes for people with dementia: building on the work of the National Dementia Strategy. London: Stationary Office; 2010. Available on http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_119827 webcite(accessed 14th April)
• [16]Maidment ID, Fox C, Boustani M, Katona C: Medication management – the missing link in dementia interventions. Int J Geriatr Psychiatry 2011.
• [17]Medway Council: Population. 2010. Available onhttp://www.medway.gov.uk/pdf/Population%20July%202011.pdf webcite (accessed 31st March 2012)
• [18]Medway Council: Index of Deprivation. 2010. Available on http://www.medway.gov.uk/pdf/Indices%20of%20Deprivation%202010.pdf webcite (accessed 31st March 2012)
• [19]Health and Social Care Information Centre (HSCIC): The Quality and Outcomes Framework. 2010/11. Available on http://www.ic.nhs.uk/qof webcite (accessed 31st July 2012)
• [20]National Audit Office: Improving Dementia Services in England – an Interim Report: GP Survey Results. 2010. Available on http://www.nao.org.uk/default.aspx webcite (accessed 31st July 2012)
• [21]BMA / RPS (British Medical Association / Royal Pharmaceutical Society): British National Formulary 62. Basingstoke: Pharmaceutical Press; 2011.
• [22]Alzheimer’s Society: Optimising treatment and care for behavioural and psychological symptoms of dementia: A best practice guide. London: Alzheimer’s Society; 2011. Available on http://www.alzheimers.org.uk/site/scripts/download_info.php?fileID=1163 webcite(accessed 14th April 2012)
• [23]NHS Kent: Treatment of behaviour in dementia that challenges. 2011. Available on http://www.easternandcoastalkent.nhs.uk/home/independent-contractors/medicines-management/drug-formulary-and-prescribing-policies/central-nervous-system/ webcite (accessed 31st July 2012)
• [24]Medicines and Health Regulatory Authority (MHRA): Anti-psychotics: use in elderly people with dementia. Drug Safety Update 2009, 2, 8. Available on http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON088116 webcite(accessed 14th February 2012)
• [25]National Prescribing Centre: Medication Review reference – Guide to medication review 2008. NPC Plus; 2008. http://www.npc.nhs.uk/review_medicines/intro/resources/agtmr_web1.pdf webcite (accessed 24th September 2012)
• [26]GraphPad Software Inc: Analyze a 2 x 2 contingency table. 2005. Available on http://www.graphpad.com/quickcalcs/contingency2.cfm webcite (accessed 23rd March 2012)
• [27]Connolly A, lliffe S, Gaehl E, Campbell S, Drake A, Morris J, Purandare N: Quality of care provided to people with dementia: utilisation and quality of the annual dementia review in general practice. Br J Gen Pract 2012, 62:e91-e98.
• [28]Goodwin N, Curry N, Naylor C, Ross S, Duldig W: Managing people with long-term conditions – an inquiry into the quality of General Practice in England. London: The King’s Fund; 2010. Available on www.kingsfund.org.uk/document.rm?id=8757 (accessed 25th March 2012)
• [29]Alzheimer’s Society: PCT dementia prevalence and diagnosis rates. Available on http://www.alzheimers.org.uk/site/scripts/directory_home.php?directoryID=13 webcite (accessed 24th March 2012)
• [30]Cameron A: QOF Dementia register size vs. Expected Dementia prevalence. Letter – NHS Dumfries and Galloway. 2010. Available on http://www.qihub.scot.nhs.uk/media/216077/appendix2.pdf webcite (accessed 11th April 2012)
• [31]Connelly PJ, Law E, Angus S, Prentice N: Fifteen year comparison of anti-psychotic use in people with dementia within hospital and nursing home settings: sequential cross sectional study. Int J Geriatr Psychiatry 2010, 25:160-165.
• [32]Bishara D, Taylor D, Howard RJ, Abdel-Tawab R: Expert opinion on the management of behavioural and psychological symptoms of dementia (BPSD) and investigation into prescribing practices in the UK. Int J Geriatr Psychiatry 2009, 24:944-954.
• [33]Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA: CATIE-AD Study Group. Effectiveness of atypical anti-psychotic drugs in patients with Alzheimer’s disease. N Engl J Med 2006, 355:1525-1538.
• [34]Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG: Efficacy and Comparative Effectiveness of Atypical Anti-psychotic Medications for Off-Label Uses in Adults - A Systematic Review and Meta-analysis. JAMA 2011, 306:1359-1369.
• [35]Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, Lucas JA, Schneeweiss S: Differential risk of death in older residents in nursing homes prescribed specific anti-psychotic drugs: population based cohort study. BMJ 2012, 344:e977.
• [36]Committee on Safety of Medicines: Atypical Anti-psychotics and stroke. 2004. Available on http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con019488.pdf webcite (accessed 14th February 2012)
• [37]Maidment I, Fox C, Katona C: An evaluation of an outreach role for specialist mental health pharmacists. International Conference on Alzheimer’s Disease. Paris: International Meeting; 2011.